20 August 2015AmericasMark Biernacki and Cameron Weir
From profits to damages: Canada’s NIA defence
On July 23, 2015, in Apotex v Merck & Co, Canada’s Federal Court of Appeal found for the first time that the availability to an infringer of a non-infringing alternative (NIA) is a relevant consideration when calculating damages for patent infringement. This is a significant legal development.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
10 February 2026 Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.
9 February 2026 The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.